Chichina

There is no image.

Carbazochrome

Method of action: Antihemorrhagics

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Chichina

Quick Facts: Carbazochrome

Property	Description
Active ingredient	Carbazochrome (Adrenochrome monosemicarbazone)
Form	Oral (tablet, capsule), Parenteral (injection)
Pharmacological class	Systemic Hemostatic Agent, Capillary Stabilizer
General purpose	To control and reduce capillary bleeding
Origin	Synthetic, derived from adrenaline (epinephrine)

Carbazochrome: Identity and Pharmacological Class

The medicine Chichina contains the active ingredient Carbazochrome, which is formally classified as a Systemic Hemostatic Agent and Antihemorrhagic Agent. It is assigned the ATC code B02BX02, placing it among "Other systemic hemostatics." Carbazochrome, whose chemical designation is Adrenochrome monosemicarbazone, is a synthetic small molecule derived as an oxidation product of adrenaline (epinephrine). Its hemostatic property is characterized by an influence on the microvasculature. Another recognized brand containing the same active substance is Adona, both being utilized in certain regulatory regions for their specific action on capillary bleeding.

Composition and Forms

Carbazochrome is prepared as a single-ingredient product and is available in multiple dosage forms, facilitating its use across various therapeutic settings. It is supplied for both oral use in the form of tablets, capsules, or fine granules, and for parenteral use as sterile injectable solutions or powders for injection. This distinction in forms allows for the medicine to be used either for rapid systemic action via injection (intramuscular, subcutaneous, or intravenous) or for less urgent, continued management using the oral preparations. Injectable preparations typically utilize an aqueous or saline base, while oral forms contain standard pharmaceutical excipients.

General Purpose: Stabilizing Microcirculation

The primary purpose of Carbazochrome is to act as a capillary stabilizer to support the integrity of the microcirculation system. Carbazochrome acts by reducing vessel fragility and inhibiting hyperpermeability (excessive leakage) of the capillary walls. This action is utilized in the management of hemorrhage associated with microcirculatory defects. A typical scenario involves using the medicine to control and reduce diffused capillary bleeding (oozing) that may occur following minor procedures or where increased vascular fragility is present.

What side effects are possible with Chichina?

The safety profile of Chichina (Carbazochrome) is officially documented by regulatory authorities through classifications that categorize adverse reactions by frequency and affected system-organ class. The most commonly noted adverse reactions involve the Gastrointestinal and Nervous System Disorders.

Less frequently, reactions involving the Immune System and Skin and Subcutaneous Tissue are documented. The safety profile explicitly lists the potential for rare, serious adverse reactions such as anaphylaxis or shock, which represent severe hypersensitivity manifestations. Other documented effects include the appearance of a harmless orange-yellow discoloration of urine and local reactions like pain at the injection site when the medicine is administered parenterally.

Safety limitations are defined by official constraints. The medicine is contraindicated in individuals with a known hypersensitivity to the active substance or its components. Caution is advised for use in individuals with severe cardiovascular disease or pre-existing blood clotting disorders. Safety and efficacy in pregnant women, nursing mothers, and pediatric patients have not been conclusively established, and use in these groups is generally based on medical necessity.

Overdose and Emergency Response

The regulatory information concerning an overdose of Chichina (Carbazochrome) centers on the mandatory need for professional medical intervention. Official government prescribing documents do not explicitly detail a specific, characteristic profile of clinical signs, symptoms, or laboratory findings associated with Carbazochrome overexposure.

Overdose and Immediate Action

Due to the absence of specific documented manifestations, any suspicion of an overdose constitutes an emergency help-seeking trigger. When intake exceeds the prescribed dose, patients are instructed to consult with a doctor or pharmacist immediately. For parenteral formulations administered in a clinical setting, emergency medical treatment will be initiated by a healthcare professional if an overdose is suspected.

Management and Regulatory Context

The official overdose structure confirms that no specific pharmacological antidote is listed for Carbazochrome in regulatory labels. Consequently, the management strategy is non-specific, aligning with standard clinical practice of providing symptomatic and supportive treatment and monitoring.

Regulatory documentation does not specify population-based overdose risks (such as those for the elderly or patients with organ impairment) or mandate specific continuous hospital observation periods. The official guidance requires urgent medical assistance to facilitate immediate professional evaluation and supportive care.

Therapeutic Uses of Chichina

Chichina (Carbazochrome) is classified as a systemic hemostatic agent that is considered relevant for easing symptoms related to various forms of abnormal bleeding. Its use is commonly applied in addressing conditions where symptoms are linked to organ-specific functional stress involving the smallest blood vessels. The medication is utilized in addressing capillary and parenchymal hemorrhage, intestinal bleeding, and thrombocytopenic purpura.

Stabilization and Supportive Relief

This medication is applied across domains where additional symptomatic support is needed to address symptom clusters like diffused capillary oozing, epistaxis (nosebleeds), bleeding gums, and mucosal bleeding from internal tracts. It supports the patient during difficult episodes by easing distress associated with conditions characterized by periods of heightened symptoms.

Quick Fact: Support in Acute Bleeding

Context	Symptom/Condition
Perioperative Care	Symptoms related to physical discomfort from bleeding during and after surgery.
Vascular Fragility	Bleeding tendency linked to capillary weakness.

Chichina is applied in clinical settings that involve acute or unstable symptom patterns during the perioperative phase or post-traumatic phases. It assists with maintaining stability by helping ease the overall symptom load.

Eligibility and Restrictions for Use

Official Regulatory Eligibility for Carbazochrome

The eligibility for using Carbazochrome (Chichina) is determined by regulatory-defined restrictions, contraindications, and special precautions, primarily based on patient health status and demographics.

Classification	Population/Condition	Regulatory Status
Absolute Contraindication	Known allergy or hypersensitivity to Carbazochrome or its components.	Must not use
Conditional Use/Caution	Pregnancy and Lactation (Breastfeeding).	Not recommended unless absolutely necessary due to insufficient data.
Conditional Use/Caution	Hepatic Impairment (Liver disorders).	Use with caution; close monitoring of liver function is advised.
Conditional Use/Caution	Renal Impairment (Kidney problems).	Use with caution; dose adjustment may be required.

Age-Related Eligibility: The medicine is typically prescribed following adult dosing guidelines for systemic hemostasis. Specific safety and efficacy profiles for the pediatric population are often not explicitly established in regulatory summaries, meaning use is generally only under medical supervision. No universal restrictions are documented for older adults (geriatric population).

Resulting Eligibility Structure: Official documentation establishes hypersensitivity as the single absolute contraindication. Other restrictions are defined as conditional use, requiring special medical caution and monitoring for specific groups where human safety data is limited, such as in pregnancy, lactation, and individuals with impaired organ function.

What should I know about interactions with other medicines?

The official regulatory profile for Chichina (Carbazochrome) primarily addresses pharmacodynamic interference and diagnostic constraints, as explicit and detailed pharmacokinetic (PK) interaction data are largely absent from official prescribing information.

Interaction Scope

Category	Regulatory Status
Medicinal Product Categories	Co-administration requires caution with medicinal products that affect the coagulation cascade or platelet function, such as Anticoagulants or Fibrinolytic agents. These agents carry a potential risk of antagonistic pharmacodynamic effects.
Mechanistic Basis	Interactions are primarily Pharmacodynamic (PD). Official regulatory documents do not provide specific, mandatory statements regarding CYP enzyme or drug transporter-mediated (PK) interactions.
Timing-Based Rules	No mandatory timing requirements (e.g., separation by a specific number of hours) for concurrent medication administration are explicitly documented in the official regulatory prescribing information.
Procedural Constraint	The medicine may cause interference with certain laboratory tests and diagnostic values. This constraint on use is documented and requires attention when diagnostic procedures are scheduled.

Resulting Interaction Structure

Formal contraindicated combinations based on drug-drug interaction mechanisms are not explicitly listed across the main regulatory documents. Interaction relevance is defined as requiring caution for any agent that may counter the hemostatic activity of Carbazochrome. Furthermore, official notes advise caution in patients with liver impairment, which could potentially impact the clearance and effect of co-administered medicines. This structure adheres strictly to the neutral interaction information provided by national regulatory authorities.

Mechanism of Action

Chichina is a small molecule designed to selectively inhibit the RANKL-mediated signaling pathway. The drug acts by binding directly to the RANKL receptor on the surface of pre-osteoclast cells. This binding action blocks the downstream cascade, including the activation of NF-kappaB and NFATc1 transcription factors, which are essential for pre-osteoclast differentiation and maturation into active osteoclasts. By limiting the formation of new osteoclasts, Chichina reduces the overall rate of bone resorption, resulting in decreased osteoclast-mediated bone resorption. This modulation affects the physiological balance between bone resorption and formation, and the reduction in bone resorption is a determinant of bone mineral density.

Dosage and Administration Information

How Chichina is Used: Administration Guidelines

The usage of Chichina, which contains the active ingredient Carbazochrome, follows established protocols that specify the routes, standard dosing, and timing requirements. These parameters define the usage of the medicine based on common prescribing information.

Administration Scope and Dosage

Category	Instruction / Detail
Route of Administration	Oral (tablet, capsule) or Parenteral (Intramuscular (IM) and Subcutaneous (SC)).
Oral Dosing Schedule	Adults typically take 10 mg to 30 mg of the active ingredient per dose.
Parenteral Dosing Schedule	The usual dose for IM or SC injection ranges from 1.5 mg to 5 mg.
Frequency Pattern	Oral use is typically three times a day (TID). Parenteral use is determined by symptoms or is tied to specific medical events.

Procedural and Timing Requirements

Standard practices establish specific conditions for administering Carbazochrome:

Timing with Meals: Oral doses are to be taken preferably one hour before meals, which establishes a condition for proper intake.
Special Administration: For use around surgery, an injection may be scheduled approximately 30 minutes before the surgical intervention. The Intravenous (IV) route is typically used only in specific emergency circumstances.
Missed Dose Rule: If a dose is missed, it is generally taken when remembered. However, instructions typically specify not to take two doses at one time to compensate for the missed dose.
Population Guidance: Dosage may be adjusted based on the patient’s age and symptoms. Caution is generally advised when administering the medicine to older adults.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Carbazochrome (Chichina)

Evidence for Use in Major Surgery

Carbazochrome was studied for its application in patients undergoing major orthopedic procedures, primarily Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA). Randomized Controlled Trials (RCTs) are the primary source of this evidence, often aggregated through meta-analyses. Studies monitored outcomes related to physiological strain or stress, specifically looking at measured amounts of blood loss and the necessity for blood product transfusions. Studies report how patterns of measured blood loss and transfusion frequency were described in surgical settings. Research provides insight into short-term changes but evidence is limited regarding the medicine's independent contribution, as it is often studied in combination with other anti-bleeding agents. Follow-up durations were limited, meaning there is limited information for long-term outcomes exploring functional recovery.

Evidence for Managing Acute Bleeding and Vascular Fragility

Research examined contexts involving acute or significant bleeding episodes, such as those related to trauma. This evidence is typically based on Retrospective Cohort Studies and Observational Studies. Researchers monitored physiological strain or stress and examined outcomes such as the total volume of blood products needed and the occurrence of in-hospital mortality. Findings were mixed regarding changes in the overall use of blood products, and the available data show patterns related to no significant change in overall high-impact outcomes in these specific contexts. The certainty remains low due to the reliance on retrospective data.

For conditions marked by vascular fragility, small-scale trials explore short-term symptom changes and patient-reported outcomes. The data are still emerging, and the sample sizes were modest, which limits the generalizability of the findings. Comparative evidence is lacking for long-term management in this context.

Evidence Gaps and Limitations

Currently, there is limited information for long-term outcomes across all studied indications. Furthermore, data for certain groups remain insufficient, particularly pregnant individuals or very young children, meaning the results apply only to the populations studied. The overall evidence quality varies across studies and the findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Frequently Asked Questions (FAQ)

Common questions about Chichina (FAQ)

Q: Are there any long-term side effects associated with Chichina use?

Official product information primarily details adverse reactions that were observed during short-term clinical use. According to regulatory documents, the long-term safety profile of the medicine is not yet comprehensively established in the available evidence from clinical trials.

Q: Can Chichina affect my ability to drive or operate machinery?

The official safety profile lists Nervous System Disorders as commonly noted adverse reactions, which can include symptoms like dizziness. The official safety profile indicates a potential need for caution regarding activities that require attention, such as driving or operating machinery, if side effects like dizziness are experienced.

Q: Is it normal to feel slightly dizzy when first starting Chichina?

The official safety profile lists Nervous System Disorders as commonly noted adverse reactions. The appearance of dizziness is consistent with the established safety information for this medicine.

Q: What is the recommended period of time to use Chichina?

Official administration guidelines indicate that the total treatment duration is not fixed by regulatory bodies. The period of use is typically determined by the specific condition being addressed, as the duration is not fixed in the regulatory guidelines.

Q: What is the general success rate described in clinical trials for Chichina?

Studies reviewed by regulatory bodies examine how the medicine affects physiological outcomes, such as measured amounts of blood loss and the necessity for blood product transfusions. The findings describe patterns observed across groups of participants and do not provide a specific individual success percentage.

Q: How quickly should someone expect Chichina to start working?

According to official documents, the amount of time required for this medicine to show its action is not clinically established or documented. This information is often related to the medicine's specific formulation and individual body response.

Q: Can Chichina be taken at the same time as common vitamins or supplements?

Official regulatory documents generally focus on drug-drug interactions. Currently, there are no specific, mandatory statements regarding known interactions between the medicine and most common vitamins or supplements.

Q: What foods or beverages are generally recommended to avoid while taking Chichina?

Regulatory information does not list specific food or beverage restrictions for this medicine. Drug-food interactions are described in official regulatory texts as not found or established.

Q: What happens if I stop taking Chichina suddenly?

Official guidance indicates that abrupt discontinuation of the medicine should not occur unless a healthcare professional directs it. This procedure is common for many prescription medicines and aligns with general safety procedures.

Q: Are there any known interactions between Chichina and common cold medicines?

Regulatory documents state that no drug-drug interactions are found or established with most medicines. An exception is noted for medicines that affect the coagulation cascade or platelet function, where caution is required due to potential pharmacodynamic effects.

Q: Can Chichina interact with birth control pills?

Official regulatory documents state that no specific drug-drug interactions are found or established for this medicine.

Q: Is Chichina addictive or habit-forming?

Official documents state that no habit-forming tendencies were reported for this medicine based on the available safety data.

Q: Does Chichina interact with caffeine or alcohol?

Official product information indicates that the interaction with alcohol is unknown. There are no specific statements regarding an interaction with caffeine.

Q: Does Chichina interact with grapefruit juice?

Regulatory documents state that no drug-food interactions are found or established for this medicine, including with specific fruit juices like grapefruit juice.

Q: What are the general expectations about the duration of Chichina's effects after one dose?

Official documents state that the amount of time the medicine remains active in the body is not clinically established or documented. This information is often not provided in the detailed pharmacokinetic documentation for the medicine.

How should Chichina be stored and disposed of?

Storage and Handling Requirements

Official regulatory labeling dictates specific conditions for storing Chichina (Carbazochrome) to maintain its stability and effectiveness as a hemostatic agent:

Storage Requirement	Condition
Temperature Range	Store at controlled room temperature, typically below 25 C or 30 C as defined by the manufacturer.
Environmental Protection	Protect from light and store in a dry place (low moisture).
Container & Handling	Keep the medicine in its original package and the container tightly closed. Do not freeze the product.
Child Safety	Mandatory to keep out of the reach of children.

Disposal Instructions

Unused or expired Chichina must be handled as pharmaceutical waste. Do not dispose of the medicine via wastewater or household waste. The proper procedure is to discard the unused product according to local regulations for medicinal waste, which prevents environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Japan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z